The virtual awards ceremony of the 6th edition of the “Israel Innovation Awards” took place on July 14th. The event was organized by the Ministry of Science, Technology and Innovation of the Argentine Republic, the Israeli Embassy in Argentina and the Argentine-Israel Chamber of Commerce. The event featured the participation of…
Bioinnovo, a public-private partnership between INTA and Vetanco S.A., will allocate an important support, granted by the Ministry of Productive Development, to increase the production of Vedevax Block in order to meet local demand and open new international markets. This is the first subunit vaccine…
Algenex, the Spanish company delivering recombinant technologies, a key factor for the development of Vedevax BLOCK, has opened a new production plant for vaccines in the suburbs of Madrid*. The new facility has the capacity to manufacture up to 3.5 kg of recombinant proteins a…
Specialists of the National Institute of Industrial Technology (INTI) and the national company Ivema Desarrollos designed an essential device for a rapid diagnostic test to substitute imports, reduce costs to the half and meet the local demand that is currently with a shortage of stock. This device…
The Andean Country authorized the commercialization of Vedevax Block, the first recombinant vaccine for the control of the virus. The product developed by Bioinnovo SA, a company created by a partnership between the National Institute of Agricultural Technology (INTA) of Argentina and the company Vetanco…
Bioinnovo, the public-private company (INTA–Vetanco) made its first contribution to the macro collaborative project conducted by a scientific committee that brings together more than twenty male and female researchers from different institutions. Those institutions are the Institute of Science and Technology César Milstein (Conicet –…
Following the signing of a Memorandum of Understanding/Cooperation Agreement (MOU) between the MIT startup Sunflower and Bioinnovo, Kerry Love, PhD and Laura Crowell, PhD visited Vetanco at its corporate headquarters. The purpose of the meeting was to ratify the MOU, which detailed the scope of work optimizing several innovative platforms using…
Argentina’s Bioinnovo has updated its partnership with Spanish firm Algenex for the use of a molecule developed by the latter The renewed partnership provides Bioinnovo with the international rights to use Algenex’s APCH (antigen presenting cells homing) molecule in the _eld of animal health. Bioinnovo…
Bioinnovo, the technology-based public-private company formed by the National Institute of Agricultural Technology (INTA) and Vetanco SA, agree to renew their contract with Algenex for the use of the APCH molecule, the targeting protein of the innovative vaccine Vedevax BLOCK. After many years of successful…
Representatives of Vetanco met with university authorities to discuss a license contract for a recombinant vaccine, with the aim of marketing it in all American countries. Four professionals from Vetanco Argentina, headed by its president Jorge Winokur, visited the University of Concepción, Chile, to discuss the details…